GPX7

Summary

GPX7 (glutathione peroxidase 7, HGNC:4559) is a protein-coding gene on chromosome 1p32.3, encoding Glutathione peroxidase 7 (Q96SL4). It protects esophageal epithelia from hydrogen peroxide-induced oxidative stress.

Enables catalase activity. Predicted to be involved in cellular response to oxidative stress. Located in endoplasmic reticulum. Implicated in Barrett’s adenocarcinoma and Barrett’s esophagus.

Source: NCBI Gene 2882 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 27 total
• MANE Select transcript: NM_015696

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4559
Approved symbol	GPX7
Name	glutathione peroxidase 7
Location	1p32.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14777, GPX6, NPGPx
Ensembl gene	ENSG00000116157
Ensembl biotype	protein_coding
OMIM	615784
Entrez	2882

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000361314, ENST00000459779

RefSeq mRNA: 1 — MANE Select: NM_015696 NM_015696

CCDS: CCDS569

Canonical transcript exons

ENST00000361314 — 3 exons

Exon	Start	End
ENSE00000835736	52606684	52606945
ENSE00001434677	52602371	52602547
ENSE00001435777	52608262	52609051

Expression profiles

Bgee: expression breadth ubiquitous, 198 present calls, max score 90.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.8313 / max 121.1757, expressed in 1350 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
2878	13.8313	1350

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	90.07	gold quality
ventricular zone	UBERON:0003053	88.49	gold quality
cartilage tissue	UBERON:0002418	87.22	gold quality
ganglionic eminence	UBERON:0004023	85.70	gold quality
periodontal ligament	UBERON:0008266	84.50	silver quality
gall bladder	UBERON:0002110	84.28	gold quality
granulocyte	CL:0000094	83.88	gold quality
right lobe of thyroid gland	UBERON:0001119	83.70	gold quality
left lobe of thyroid gland	UBERON:0001120	83.50	gold quality
adenohypophysis	UBERON:0002196	82.71	gold quality
thyroid gland	UBERON:0002046	82.56	gold quality
embryo	UBERON:0000922	82.28	gold quality
left uterine tube	UBERON:0001303	82.19	gold quality
endocervix	UBERON:0000458	82.15	gold quality
ascending aorta	UBERON:0001496	81.93	gold quality
islet of Langerhans	UBERON:0000006	81.87	gold quality
descending thoracic aorta	UBERON:0002345	81.87	gold quality
thoracic aorta	UBERON:0001515	81.82	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.80	gold quality
stromal cell of endometrium	CL:0002255	81.60	gold quality
pituitary gland	UBERON:0000007	81.55	gold quality
hindlimb stylopod muscle	UBERON:0004252	81.46	gold quality
bone marrow	UBERON:0002371	81.17	gold quality
tibia	UBERON:0000979	81.06	gold quality
endometrium	UBERON:0001295	81.02	gold quality
left coronary artery	UBERON:0001626	81.01	gold quality
body of pancreas	UBERON:0001150	80.88	gold quality
mucosa of stomach	UBERON:0001199	80.83	gold quality
cortical plate	UBERON:0005343	80.80	gold quality
body of uterus	UBERON:0009853	80.79	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.99
E-MTAB-6379	no	211.89
E-MTAB-9543	no	1.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

61 targeting GPX7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548AW	99.99	72.57	3559
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-767-5P	99.95	70.85	993
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-498-3P	99.91	71.27	1114
HSA-MIR-3671	99.90	73.04	3897

Literature-anchored findings (GeneRIF, showing 15)

• NPGPx plays an essential role in breast cancer cells in alleviating oxidative stress generated from polyunsaturated fatty acid metabolism (PMID:15294905)
• GPx7 labeled as secreted glutathione peroxidase, is actually endoplasmic reticulum-resident protein disulfide isomerase peroxidase (PMID:21215271)
• NPGPx is essential for releasing excessive ER stress by enhancing GRP78 chaperone activity to maintain physiological homeostasis. (PMID:23123197)
• GPx7 is an unusual CysGPx catalyzing the peroxidatic cycle by a one Cys mechanism in which GSH and PDI are alternative substrates. (PMID:23454490)
• tumour suppressor functions in esophageal adenocarcinomas and silenced by location-specific promoter DNA methylation (PMID:23580780)
• NPGPx protects against fat accumulation in mice and human via modulating ROS (PMID:23828861)
• GPx7 promotes oxidative protein folding, directly utilizing Ero1alpha-generated hydrogen peroxide in the early secretory compartment. (PMID:23919619)
• Loss of glutathione peroxidase 7 promotes TNF-alpha-induced NF-kappaB activation in Barrett’s carcinogenesis. (PMID:24692067)
• SNPs most associated with Chemotherapy-induced peripheral neuropathy were in ATP-binding cassette sub-family C member 4 (ABCC4) gene. (PMID:25586538)
• use GPX4 and GPX7 as possible markers for improving HCC diagnosis/prognosis. (PMID:26708178)
• Characterization of the endoplasmic reticulum-resident peroxidases GPx7 and GPx8 shows the higher oxidative activity of GPx7 and its linkage to oxidative protein folding. (PMID:32719007)
• MicroRNAs mediated regulation of glutathione peroxidase 7 expression and its changes during adipogenesis. (PMID:34339889)
• GPX7 Facilitates BMSCs Osteoblastogenesis via ER Stress and mTOR Pathway. (PMID:34626080)
• Comprehensive analysis of epigenetics regulation, prognostic and the correlation with immune infiltrates of GPX7 in adult gliomas. (PMID:35440701)
• GPX7 reduces chondrocyte inflammation and extracellular matrix degradation triggered by IL-1beta, via a mechanism mediated by ferroptosis. (PMID:38757339)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpx7	ENSDARG00000091511
mus_musculus	Gpx7	ENSMUSG00000028597
rattus_norvegicus	Gpx7	ENSRNOG00000009751
caenorhabditis_elegans		WBGENE00007516
caenorhabditis_elegans		WBGENE00007517
caenorhabditis_elegans		WBGENE00011045
caenorhabditis_elegans	gpx-8	WBGENE00018850
caenorhabditis_elegans		WBGENE00022377

Paralogs (7): GPX8 (ENSG00000164294), GPX4 (ENSG00000167468), GPX2 (ENSG00000176153), GPX6 (ENSG00000198704), GPX3 (ENSG00000211445), GPX5 (ENSG00000224586), GPX1 (ENSG00000233276)

Protein

Protein identifiers

Glutathione peroxidase 7 — Q96SL4 (reviewed: Q96SL4)

Alternative names: CL683

All UniProt accessions (1): Q96SL4

UniProt curated annotations — full annotation on UniProt →

Function. It protects esophageal epithelia from hydrogen peroxide-induced oxidative stress. It suppresses acidic bile acid-induced reactive oxygen species (ROS) and protects against oxidative DNA damage and double-strand breaks.

Subcellular location. Secreted.

Tissue specificity. Expressed in esophageal epithelial cells; expression is up-regulated after exposure to acidic bile acids.

Disease relevance. Barrett esophagus (BE) [MIM:614266] A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes. The disease is caused by variants affecting the gene represented in this entry. The pathologic mechanisms leading to Barrett esophagus involve GPX7 dysfunction that results in higher levels of hydrogen peroxide and ROS-induced oxidative stress and DNA damage in esophageal cells.

Similarity. Belongs to the glutathione peroxidase family.

RefSeq proteins (1): NP_056511* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000889	Glutathione_peroxidase	Family
IPR013376	Glut_perox_Gpx7	Family
IPR029759	GPX_AS	Active_site
IPR029760	GPX_CS	Conserved_site
IPR036249	Thioredoxin-like_sf	Homologous_superfamily

Pfam: PF00255

Enzyme classification (BRENDA):

• EC 1.11.1.9 — glutathione peroxidase (BRENDA: 58 organisms, 96 substrates, 65 inhibitors, 63 Km, 23 kcat entries)

Substrate kinetics (BRENDA)

12 substrates with measured Km, best-characterized 12. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
H2O2	0.0023–19.08	19
GSH	0.033–11.1	18
CUMENE HYDROPEROXIDE	0.006–7.8	6
TERT-BUTYL HYDROPEROXIDE	0.059–7.9	6
GLUTATHIONE	0.022–1.73	4
CUMENE PEROXIDE	0.09–0.42	2
L-ALPHA-PHOSPHATIDYLCHOLINE HYDROPEROXIDE	0.026–9.7	2
LINOLENIC ACID HYDROPEROXIDE	0.007–3.8	2
CHOLESTEROL 5ALPHA-HYDROPEROXIDE	0.004	1
CHOLESTEROL 7ALPHA-HYDROPEROXIDE	0.011	1
CHOLESTEROL 7BETA-HYDROPEROXIDE	0.003	1
TERT-BUTYLHYDROPEROXIDE	0.024	1

Catalyzed reactions (Rhea), 1 shown:

• 2 glutathione + H2O2 = glutathione disulfide + 2 H2O (RHEA:16833)

UniProt features (18 total): helix 7, strand 7, signal peptide 1, chain 1, active site 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2P31	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96SL4-F1	93.24	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 57

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-3299685	Detoxification of Reactive Oxygen Species

MSigDB gene sets: 176 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, CHANDRAN_METASTASIS_DN, GOBP_CELLULAR_RESPONSE_TO_TOXIC_SUBSTANCE, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, GOBP_DETOXIFICATION, GGCAGTG_MIR3243P, GOMF_ANTIOXIDANT_ACTIVITY, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PEROXIDE_AS_ACCEPTOR, GOBP_RESPONSE_TO_TOXIC_SUBSTANCE, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP, ACEVEDO_LIVER_CANCER_UP, GOCC_ENDOPLASMIC_RETICULUM_LUMEN, SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP, GOMF_GLUTATHIONE_PEROXIDASE_ACTIVITY, KEGG_GLUTATHIONE_METABOLISM

GO Biological Process (3): cellular response to oxidative stress (GO:0034599), response to oxidative stress (GO:0006979), cellular oxidant detoxification (GO:0098869)

GO Molecular Function (5): catalase activity (GO:0004096), peroxidase activity (GO:0004601), glutathione peroxidase activity (GO:0004602), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (3): extracellular region (GO:0005576), endoplasmic reticulum (GO:0005783), endoplasmic reticulum lumen (GO:0005788)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Cellular response to chemical stress	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peroxidase activity	2
response to oxidative stress	1
cellular response to chemical stress	1
response to stress	1
cellular detoxification	1
antioxidant activity	1
oxidoreductase activity, acting on peroxide as acceptor	1
binding	1
catalytic activity	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
endoplasmic reticulum	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

3544 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPX7	GSR	P00390	968
GPX7	TXN	P10599	902
GPX7	XDH	P47989	884
GPX7	F5H3C5	F5H3C5	858
GPX7	SOD2	P04179	858
GPX7	TXNRD1	Q16881	844
GPX7	GLRX	P35754	842
GPX7	HMOX1	P09601	837
GPX7	SOD1	P00441	828
GPX7	GPT	P24298	813
GPX7	H6PD	O95479	803
GPX7	G6PD	P11413	802
GPX7	NFE2L2	Q16236	800
GPX7	TXNRD3	Q86VQ6	790
GPX7	MSRB1	Q9NZV6	780

IntAct

61 interactions, top by confidence:

A	B	Type	Score
GPX7	GET3	psi-mi:“MI:0915”(physical association)	0.720
GET3	GPX7	psi-mi:“MI:0915”(physical association)	0.720
SGTA	GPX7	psi-mi:“MI:0915”(physical association)	0.700
GPX7	SGTA	psi-mi:“MI:0915”(physical association)	0.700
GPX7	GAK	psi-mi:“MI:0914”(association)	0.640
TGIF2LY	PGP	psi-mi:“MI:0914”(association)	0.640
CEP70	GPX7	psi-mi:“MI:0915”(physical association)	0.560
GPX7	CEP70	psi-mi:“MI:0915”(physical association)	0.560
GPX7	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
GPX7	CPNE7	psi-mi:“MI:0915”(physical association)	0.560
NTAQ1	GPX7	psi-mi:“MI:0915”(physical association)	0.560
GPX7	TCF25	psi-mi:“MI:0915”(physical association)	0.560
NCALD	GPX7	psi-mi:“MI:0915”(physical association)	0.560
SGTB	GPX7	psi-mi:“MI:0915”(physical association)	0.560
ASPH	GPX7	psi-mi:“MI:0915”(physical association)	0.560
DMWD	GPX7	psi-mi:“MI:0915”(physical association)	0.560
GPX7	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
HTT	GPX7	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (94): HSPA5 (Affinity Capture-MS), HSPA9 (Affinity Capture-MS), PDIA4 (Affinity Capture-MS), EEF1A1 (Affinity Capture-MS), DNAJB11 (Affinity Capture-MS), HIST1H1B (Affinity Capture-MS), HSPA5 (Affinity Capture-Western), GPX7 (Affinity Capture-Western), GPX7 (Two-hybrid), CEP70 (Two-hybrid), SGTA (Two-hybrid), GPX7 (PCA), P4HB (Affinity Capture-Western), UTP6 (Affinity Capture-MS), GAK (Affinity Capture-MS)

ESM2 similar proteins: A4FV98, A6NKP2, A6QLY2, O18735, O43488, O75382, O75648, O77485, O77486, O88676, P04626, P23764, P25325, P34059, P52848, Q02353, Q0VD18, Q10836, Q10981, Q10982, Q28113, Q32KH5, Q32KJ6, Q3U129, Q3UHN9, Q4R766, Q571E4, Q5I0D5, Q5RB73, Q5RJL2, Q6AYT7, Q6P988, Q7RTV5, Q7Z4H8, Q8CIW5, Q8K093, Q8N2K0, Q8WNQ7, Q96AZ1, Q96SL4

Diamond homologs: A1KV41, A6QLY2, G9JJU2, O02621, O04922, O08368, O18994, O22448, O22850, O23814, O23968, O23970, O24031, O24296, O32770, O46607, O48646, O49069, O59858, O62327, O70325, O75715, P00435, P04041, P06610, P07203, P0A0T4, P0A0T5, P0C2T0, P11352, P11909, P18283, P21765, P22352, P28714, P30708, P30710, P35666, P36014, P36968

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

27 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

628 predictions. Top by Δscore:

Variant	Effect	Δscore
1:52602543:GATCG:G	donor_gain	1.0000
1:52602548:G:GA	donor_loss	1.0000
1:52602548:G:GG	donor_gain	1.0000
1:52602549:T:A	donor_loss	1.0000
1:52606681:CAGGT:C	acceptor_loss	1.0000
1:52606682:A:AG	acceptor_gain	1.0000
1:52606683:G:GC	acceptor_gain	1.0000
1:52606683:GGT:G	acceptor_gain	1.0000
1:52606840:GAGAT:G	donor_gain	1.0000
1:52606941:GGCCC:G	donor_gain	1.0000
1:52606942:GCCC:G	donor_gain	1.0000
1:52606942:GCCCG:G	donor_gain	1.0000
1:52606946:G:GG	donor_gain	1.0000
1:52602532:G:GT	donor_gain	0.9900
1:52602545:TCG:T	donor_gain	0.9900
1:52602550:GAGT:G	donor_loss	0.9900
1:52606674:T:TA	acceptor_gain	0.9900
1:52606679:T:G	acceptor_gain	0.9900
1:52606680:ACAG:A	acceptor_gain	0.9900
1:52606681:C:G	acceptor_gain	0.9900
1:52606682:AG:A	acceptor_gain	0.9900
1:52606682:AGGT:A	acceptor_gain	0.9900
1:52606683:GG:G	acceptor_gain	0.9900
1:52606683:GGTG:G	acceptor_gain	0.9900
1:52606683:GGTGT:G	acceptor_gain	0.9900
1:52606943:CCC:C	donor_gain	0.9900
1:52606944:CC:C	donor_gain	0.9900
1:52606945:CGTAA:C	donor_loss	0.9900
1:52606946:G:GC	donor_loss	0.9900
1:52606947:T:G	donor_loss	0.9900

AlphaMissense

1206 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:52608290:C:A	N143K	0.997
1:52608290:C:G	N143K	0.997
1:52606701:T:A	N52K	0.996
1:52606701:T:G	N52K	0.996
1:52606795:T:C	F84L	0.996
1:52606797:C:A	F84L	0.996
1:52606797:C:G	F84L	0.996
1:52606810:T:C	F89L	0.996
1:52606812:T:A	F89L	0.996
1:52606812:T:G	F89L	0.996
1:52608319:G:T	G153V	0.996
1:52608291:T:C	F144L	0.995
1:52608293:C:A	F144L	0.995
1:52608293:C:G	F144L	0.995
1:52606781:T:C	F79S	0.994
1:52606803:C:G	C86W	0.994
1:52606754:T:C	L70P	0.993
1:52606796:T:C	F84S	0.993
1:52606879:T:C	F112L	0.993
1:52606881:C:A	F112L	0.993
1:52606881:C:G	F112L	0.993
1:52606802:G:A	C86Y	0.992
1:52606930:T:C	F129L	0.991
1:52606932:C:A	F129L	0.991
1:52606932:C:G	F129L	0.991
1:52608299:G:C	K146N	0.991
1:52608299:G:T	K146N	0.991
1:52608307:T:A	V149E	0.991
1:52606787:T:A	V81E	0.989
1:52606811:T:G	F89C	0.989

dbSNP variants (sampled 300 via entrez): RS1000019423 (1:52603197 C>G), RS1000477403 (1:52609050 C>T), RS1000517957 (1:52609296 T>C,G), RS1000621703 (1:52601897 A>G), RS1000993913 (1:52601465 T>C), RS1001520140 (1:52607966 G>C), RS1002083918 (1:52600455 C>T), RS1002380673 (1:52604908 G>A), RS1002490190 (1:52605797 C>T), RS1002966280 (1:52609093 G>C), RS1003095540 (1:52601321 T>G), RS1003192175 (1:52603060 A>G), RS1003344038 (1:52608745 G>A), RS1006041121 (1:52609130 A>G), RS1006187606 (1:52604172 A>C)

Disease associations

OMIM: gene MIM:615784 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003998_18	Joint mobility (Beighton score)	2.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007905	joint hypermobility measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	9
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression	2
Particulate Matter	increases abundance, increases expression	2
GSK-J4	decreases expression	1
tungsten carbide	affects binding, decreases expression	1
naringenin	increases expression, affects cotreatment	1
bis(tri-n-butyltin)oxide	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	increases methylation	1
trichostatin A	increases reaction, affects expression, affects methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	increases expression	1
ochratoxin A	decreases expression	1
cerous chloride	decreases expression, affects cotreatment	1
lanthanum chloride	affects cotreatment, decreases expression	1
nickel sulfate	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
belinostat	decreases expression	1
bisphenol B	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
incobotulinumtoxinA	decreases expression	1
(+)-JQ1 compound	decreases expression	1
bisphenol AF	increases expression	1
Decitabine	affects methylation, increases reaction, affects expression	1
Arsenic Trioxide	increases expression	1
Vorinostat	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.